The effectiveness of small molecules that interfere with the function of cytosolic CXXC5 further confirmed the CXXC5-Dvl PPI as a target for treating diseases with suppressed Wnt/β-catenin signaling, such as baldness, bone growth senescence, and metabolic diseases such as obese type 2 diabetes and nonalcoholic steatohepatitis20–23. The gene discussed is CXXC5; the disease is Other metabolic disease.